following an abbreviated submission:
doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) is accepted for use within NHSScotland.
Indication under review: for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir.
Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) offers an additional treatment choice of NNRTI-based single-tablet regimen for this indication.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice732KB (PDF)
- Medicine name:
- doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo)
- SMC ID:
For the treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Submission type
- Date advice published
- 08 March 2021